BIIB Stock Analysis: Biogen | NASDAQ
Drug Manufacturers - General | NASDAQ, USA | Market Cap: 31.907m USD | 12M Return: 49.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 247M
EPS Trend: 8.1%
Qual. Beats: 1
Rev. Trend: 3.0%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Biogen Inc. (NASDAQ: BIIB) is a global biotechnology company that discovers, develops, manufactures, and commercializes therapies, with operations spanning the United States, Europe, and Asia. Headquartered in Cambridge, Massachusetts and founded in 1978, the company has grown into a large-cap player within the Health Care sectors biotechnology sub-industry.
Its portfolio centers on treatments for neurological and neurodegenerative diseases, including multiple sclerosis therapies (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS), spinal muscular atrophy (SPINRAZA), Friedreichs Ataxia (SKYCLARYS), amyotrophic lateral sclerosis (QALSODY), and Alzheimers disease (LEQEMBI). Biogen also markets biosimilars such as BENEPALI, IMRALDI, and FLIXABI, and has expanded into adjacent areas like postpartum depression (ZURZUVAE) and oncology through partnered anti-CD20 therapies such as RITUXAN, GAZYVA, and LUNSUMIO.
The business model relies heavily on strategic collaborations and licensing agreements with partners including Eisai, Genentech, Ionis Pharmaceuticals, Alkermes, Sage Therapeutics, and Samsung Bioepis, alongside newer research alliances with firms such as Stoke Therapeutics, Denali Therapeutics, and City Therapeutics. This partnership-driven approach is a common feature in the biotechnology industry, where companies share development risk and leverage external scientific expertise to advance pipeline assets across rare diseases, neurology, and immunology.
- LEQEMBI launch momentum offsets MS franchise decline
- Cost restructuring program targets $1 billion in annual savings
- Litfilo ALS Phase 3 readout and FDA approval pending
| Net Income: 1.37b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.71 > 1.0 |
| NWC/Revenue: 62.81% < 20% (prev 23.72%; Δ 39.09% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.59b > Net Income 1.37b |
| Net Debt (2.55b) to EBITDA (2.70b): 0.94 < 3 |
| Current Ratio: 3.06 > 1.5 & < 3 |
| Outstanding Shares: last quarter (148.4m) vs 12m ago 1.71% < -2% |
| Gross Margin: 69.77% > 18% (prev 71.93%; Δ -2.16% > 0.5%) |
| Asset Turnover: 34.28% > 50% (prev 35.02%; Δ -0.74% > 0%) |
| Interest Coverage Ratio: 6.59 > 6 (EBIT TTM 1.81b / Interest Expense TTM 275.1m) |
| A: 0.21 (Total Current Assets 9.19b - Total Current Liabilities 3.00b) / Total Assets 29.5b |
| B: 0.71 (Retained Earnings 20.9b / Total Assets 29.5b) |
| C: 0.06 (EBIT TTM 1.81b / Avg Total Assets 28.8b) |
| D: 1.72 (Book Value of Equity 18.7b / Total Liabilities 10.8b) |
| Altman-Z'' = 5.92 = AAA |
| DSRI: 0.89 (Receivables 1.79b/2.00b, Revenue 9.86b/9.82b) |
| GMI: 1.03 (GM 71.93% / 69.77%) |
| AQI: 0.96 (AQ_t 0.58 / AQ_t-1 0.60) |
| SGI: 1.00 (Revenue 9.86b / 9.82b) |
| TATA: -0.04 (NI 1.37b - CFO 2.59b) / TA 29.5b) |
| Beneish M = -3.11 (Cap -4..+1) = AA |
As of July 10, 2026, the stock is trading at USD 198.91 with a total of 1,633,841 shares traded. Over the past week, the price has changed by -5.16%, over one month by -0.10%, over three months by +12.31% and over the past year by +49.53%.
Current recommended Stop Loss: 186.30 (which is 6.3% or 1.8 ATR below the current price).
Biogen has received a consensus analysts rating of 3.81. Therefore, it is recommended to buy BIIB.
- StrongBuy: 13
- Buy: 4
- Hold: 20
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 220.3 | 10.7% |
P/E Trailing = 23.2637
P/E Forward = 15.4799
P/S = 3.2108
P/B = 1.7107
P/EG = 4.5533
Revenue TTM = 9.86b USD
EBIT TTM = 1.81b USD
EBITDA TTM = 2.70b USD
Long Term Debt = 6.29b USD (from longTermDebt, last quarter)
Short Term Debt = 80.4m USD (from shortTermDebt, last fiscal year)
Debt = 6.84b USD (from shortLongTermDebtTotal, last quarter) + Leases 273.4m
Net Debt = 2.55b USD (calculated: Debt 6.84b - CCE 4.28b)
Enterprise Value = 34.5b USD (31.9b + Debt 6.84b - CCE 4.28b)
Interest Coverage Ratio = 6.59 (Ebit TTM 1.81b / Interest Expense TTM 275.1m)
EV/FCF = 13.14x (Enterprise Value 34.5b / FCF TTM 2.62b)
FCF Yield = 7.61% (FCF TTM 2.62b / Enterprise Value 34.5b)
FCF Margin = 26.61% (FCF TTM 2.62b / Revenue TTM 9.86b)
Net Margin = 13.92% (Net Income TTM 1.37b / Revenue TTM 9.86b)
Gross Margin = 69.77% ((Revenue TTM 9.86b - Cost of Revenue TTM 2.98b) / Revenue TTM)
Gross Margin QoQ = 73.32% (prev 78.23%)
Tobins Q-Ratio = 1.17 (Enterprise Value 34.5b / Total Assets 29.5b)
Interest Expense / Debt = 4.02% (Interest Expense 275.1m / Debt 6.84b)
Taxrate = 6.51% (95.6m / 1.47b)
NOPAT = 1.70b (EBIT 1.81b * (1 - 6.51%))
Current Ratio = 3.06 (Total Current Assets 9.19b / Total Current Liabilities 3.00b)
Debt / Equity = 0.37 (Debt 6.84b / totalStockholderEquity, last quarter 18.7b)
Debt / EBITDA = 0.94 (Net Debt 2.55b / EBITDA 2.70b)
Debt / FCF = 0.97 (Net Debt 2.55b / FCF TTM 2.62b)
Total Stockholder Equity = 18.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.77% (Net Income 1.37b / Total Assets 29.5b)
RoE = 7.55% (Net Income TTM 1.37b / Total Stockholder Equity 18.2b)
RoCE = 7.41% (EBIT 1.81b / Capital Employed (Equity 18.2b + L.T.Debt 6.29b))
RoIC = 6.50% (NOPAT 1.70b / Invested Capital 26.1b)
WACC = 7.30% (E(31.9b)/V(38.7b) * Re(8.06%) + D(6.84b)/V(38.7b) * Rd(4.02%) * (1-Tc(0.07)))
Discount Rate = 8.06% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.07 | Cagr: 0.82%
[DCF] Terminal Value 77.86% ; FCFF base≈2.49b ; Y1≈2.84b ; Y5≈4.11b
[DCF] Fair Price = 402.5 (EV 62.0b - Net Debt 2.55b = Equity 59.4b / Shares 147.6m; r=8.35% [WACC [floored]]; 5y FCF grow 14.27% → 2.50% )
EPS Correlation: 8.13 | EPS CAGR: 0.30% | SUE: 1.17 | # QB: 1
Revenue Correlation: 3.02 | Revenue CAGR: 0.05% | SUE: 1.96 | # QB: 1
EPS current Quarter (2026-06-30): EPS=2.09 | Chg30d=+7.94% | Revisions=-75% | Analysts=22
EPS next Quarter (2026-09-30): EPS=3.94 | Chg30d=+0.10% | Revisions=+25% | Analysts=22
EPS current Year (2026-12-31): EPS=13.32 | Chg30d=-0.14% | Revisions=-77% | GrowthEPS=-12.8% | GrowthRev=+1.6%
EPS next Year (2027-12-31): EPS=16.63 | Chg30d=+0.19% | Revisions=+17% | GrowthEPS=+24.8% | GrowthRev=+3.3%
[Analyst] Revisions Ratio: -65% (up=3, down=20)